




The relative strengths and weaknesses of Sagent Pharmaceuticals Inc are analyzed with respect to the market average, including all of its competitors. We analyzed all variables having an effect on the Economic Capital Ratio.

The greatest strength of Sagent Pharmaceuticals Inc compared to the market average is the variable Liabilities, increasing the Economic Capital Ratio by 81% points. The greatest weakness of Sagent Pharmaceuticals Inc is the variable Other Expenses, reducing the Economic Capital Ratio by 42% points.

The company's Economic Capital Ratio, given in the ranking table, is 357%, being 114% points above the market average of 243%.

Input Variable	Value in 1000 USD
Assets, Current	235,791
Cost of Goods Sold	0
Intangible Assets	14,364
Liabilities, Current	63,524
Liabilities, Non-Current	2,329
Other Assets	2,369
Other Compr. Net Income	-2,013
Other Expenses	166,658
Other Liabilities	8,329
Other Net Income	7,936
Other Revenues	244,789
Property and Equipment	57,684
Research and Development	20,275
Selling, General and Administrative Expense	36,198

Output Variable	Value in 1000 USD
Assets	310,208
Liabilities	74,182
Expenses	223,131
Revenues	244,789
Stockholders Equity	236,026
Net Income	29,594
Comprehensive Net Income	28,588
BaseVar	431,130
ECR before Limited Liability	283%
Economic Capital Ratio	357%